Hims & Hers CFO Okupe sells $662k in shares

Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health, Inc. (NASDAQ:HIMS), sold 11,592 shares of Class A Common Stock on October 17, 2025, for approximately $662,221. The shares were sold at a weighted average price of $57.1275, with individual sales prices ranging from $56.93 to $57.315.

According to a Form 4 filing with the Securities and Exchange Commission, Okupe also exercised options to acquire 7,785 shares at $5.01 and 3,807 shares at $11.53, for a total value of $82,897. The company has demonstrated strong financial performance, with annual revenue reaching $2.01 billion and maintaining a healthy gross profit margin of 76%.

The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted by Okupe on May 21, 2025. Following the sale, Okupe directly owns 70,232 shares of Hims & Hers Health, Inc.

In other recent news, Hims & Hers Health has launched new perimenopause and menopause treatment options on its women’s health platform. This expansion allows customers to access personalized treatments, including estradiol and progesterone in various forms, addressing symptoms like hot flashes and sleep disturbances. The company sees this move as a significant opportunity to scale its platform, targeting a market with approximately 1.3 million women in the U.S. experiencing menopause annually. Despite this positive development, Bank of America has maintained its Underperform rating for Hims & Hers, citing concerns over weak order trends. The firm expects third-quarter revenue to align with consensus estimates but highlights a notable drop in orders in September compared to the previous year. Additionally, President Trump’s recent comments about lowering the prices of weight loss medications, including Ozempic, have impacted the stock. These developments underscore the competitive and dynamic landscape Hims & Hers is navigating.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.